Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
After a promising start to 2023, clinical-stage biotech stocks reversed course this week. For example, shares of the developmental-stage biotechs Altimmune (NASDAQ: ALT), Foghorn Therapeutics (NASDAQ: FHTX), and Precigen (NASDAQ: PGEN) all dropped by double digits during the first three and half days of trading this week, according to data provided by S&P Global Market Intelligence.
Source Fool.com